Abstract P032: Berzosertib plus irinotecan in patients with TP53 mutant gastric/gastroesophageal junction adenocarcinoma: A phase II study

2021 ◽  
Author(s):  
Satya Das ◽  
G. Dan Ayers ◽  
Jennifer Whisenant ◽  
Anwaar Saeed ◽  
Edward Kim ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gastroesophageal Junction ◽  
Gastroesophageal Junction Adenocarcinoma

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

2010 ◽  
Vol 29 (6) ◽  
pp. 1475-1481 ◽  
Author(s):  
Manish A. Shah ◽  
Derek G. Power ◽  
Hedy L. Kindler ◽  
Kyle D. Holen ◽  
Margaret M. Kemeny ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gastroesophageal Junction ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Multicenter Phase

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

2011 ◽  
Vol 13 (3) ◽  
pp. 179-184 ◽  
Author(s):  
Cristina Grávalos ◽  
Carlos Gómez-Martín ◽  
Fernando Rivera ◽  
Inmaculada Alés ◽  
Bernardo Queralt ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Study ◽  
Gastroesophageal Junction ◽  
First Line ◽  
Her2 Positive ◽  
First Line Therapy ◽  
Gastroesophageal Junction Cancer ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document